Pharmaniaga Berhad (Pharmaniaga), Pharmaniaga Lifescience Sdn Bhd (PLS) a wholly owned subsidiary of the company has entered into a Supply and Distribution Agreement with Malaysia, represented by the Ministry of Health of Malaysia (MoH) for the supply and distribution of 200,000 doses of Covid-19 vaccine Imported finished product to all facilities specified by MoH.
The finished products have been developed by Sinovac Life Sciences Co. Ltd. (Sinovac LS), a subsidiary of the Sinovac Biotech Ltd and granted a Conditional Approval of Pharmaceutical Product During Disaster by the National Pharmaceutical Regulatory Agency (NPRA) on March 2.
The agreement is to enable MoH to purchase the Imported Finished Product from PLS and for PLS to supply and distribute 200,000 doses of the Imported Finished Product to all facilities specified by the MoH.
The agreement and collaboration contemplated therein will serve as a platform for Pharmaniaga to further strengthen its vaccine business and grow the sector in Malaysia.
Additionally, it will also provide Pharmaniaga another income stream which will contribute to the profitability of the company in the future.
